Susquehanna International Securities, Ltd. Galapagos Nv Call Options Transaction History

Susquehanna International Securities, Ltd.

$389 Million
Q3 2024

Call Options

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2020 Feb 16, 2021	SELL	$96.85 - $148.25 $3.69 Million - $5.65 Million	-38,100 Reduced 92.7%	3,000 $297,000
Q3 2020 Nov 16, 2020	SELL	$122.47 - $213.56 $918,525 - $1.6 Million	-7,500 Reduced 15.43%	41,100 $5.83 Million
Q2 2020 Aug 14, 2020	SELL	$185.52 - $231.25 $2.37 Million - $2.96 Million	-12,800 Reduced 20.85%	48,600 $9.59 Million
Q1 2020 May 15, 2020	BUY	$143.0 - $274.03 $6.21 Million - $11.9 Million	43,400 Added 241.11%	61,400 $12 Million
Q4 2019 Feb 14, 2020	BUY	$146.12 - $215.82 $1.65 Million - $2.44 Million	11,300 Added 168.66%	18,000 $3.72 Million
Q3 2019 Nov 14, 2019	SELL	$130.44 - $187.64 $952,212 - $1.37 Million	-7,300 Reduced 52.14%	6,700 $1.02 Million
Q2 2019 Aug 14, 2019	SELL	$111.45 - $128.93 $3.15 Million - $3.65 Million	-28,300 Reduced 66.9%	14,000 $1.81 Million
Q1 2019 May 15, 2019	SELL	$89.61 - $117.78 $1.61 Million - $2.12 Million	-18,000 Reduced 29.85%	42,300 $4.98 Million
Q4 2018 Feb 14, 2019	BUY	$87.81 - $110.65 $5.29 Million - $6.67 Million	60,300 New	60,300 $5.53 Million

Others Institutions Holding GLPG

# of Institutions

Shares Held

12.3M

Call Options Held

69.1K

Put Options Held

42.7K

Bvf Inc San Francisco, CA

1.57M
Shares

$37.3 Million
1.44% of portfolio
Deerfield Management Company, L.P. (Series C) New York, NY

1.41M
Shares

$33.5 Million
0.76% of portfolio
Prosight Management, LP Dallas, TX

1.03M
Shares

$24.4 Million
7.95% of portfolio
Logos Global Management LP San Francisco, CA

800K
Shares

$19 Million
3.05% of portfolio
Primecap Management CO Pasadena, CA

720K
Shares

$17.1 Million
0.02% of portfolio

View Full List

About GALAPAGOS NV

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.56B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

More about GLPG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Securities, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Securities, Ltd. with notifications on news.

Account